Syneron Medical Ltd. (ELOS) said its third-quarter net loss attributable to the company's shareholders was $5.55 million or $0.20 per share versus a profit of $2.19 million or $0.08 per share last year.
On a non-GAAP basis, excluding stock-based compensation expenses, net loss in the third quarter was $4.81 million or $0.17 per share, compared with a profit of $3.08 million or $0.11 per share in the third quarter of 2008.
Revenues for the third quarter of 2009 were $14.28 million, lower than $28.49 million in the comparable period. On average, 3 analysts polled by Thomson Reuters expected loss per share of $0.15 on revenues of $14.74 million for the quarter. Analysts' estimate typically excludes one-time items.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.